ADHD
Neurology · 2005–2022
13decisions
6medicines
5carried consumer input
448individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| methylphenidate hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in adults with a retrospective diagnosis of ADHD (diagnosed after age 18). | Mar 2022 | Recommended | 131 individuals |
| lisdexamfetamine Treatment of attention deficit hyperactivity disorder (ADHD) in patients diagnosed after the age of 18 years, with retrospective confirmation of symptoms… | Mar 2020 | Recommended | 194 individuals |
| lisdexamfetamine Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years requiring continuous coverage over 12 hours. | Jul 2019 | Recommended with restriction | 116 individuals |
| guanfacine Treatment of attention deficit hyperactivity disorder (ADHD) as add-on therapy to stimulants in patients aged 6-18 years who have failed to achieve an adequate… | Jul 2018 | Recommended with restriction | none received |
| lisdexamfetamine dimesilate Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients diagnosed between the ages of 6 and 18 years (inclusive) who have demonstrated a… | Jul 2014 | Recommended | 7 individuals |
| lisdexamfetamine Treatment of attention deficit hyperactivity disorder (ADHD) in patients diagnosed between the ages of 6 and 18 years who require continuous coverage over 13… | Jul 2013 | Not recommended | input received |
| methylphenidate hydrochloride treatment of attention deficit hyperactivity disorder (ADHD) in adults diagnosed after the age of 18 years | Jul 2012 | Recommended | unclear |
| atomoxetine hydrochloride treatment of attention deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist… | Jul 2008 | Recommended with restriction | no section in document |
| methylphenidate hydrochloride extended release Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years who have demonstrated a response to immediate release… | Jul 2007 | Not recommended | no section in document |
| atomoxetine hydrochloride treatment of attention deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years by a paediatrician or psychiatrist according to the… | Jul 2006 | Not recommended | no section in document |
| Atomoxetine Hydrochloride Initial treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist… | Nov 2006 | Recommended with restriction | no section in document |
| methylphenidate hydrochloride treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-18 years who have demonstrated a response to immediate release… | Nov 2006 | Recommended with restriction | no section in document |
| atomoxetine hydrochloride Initial treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-18 years diagnosed according to DSM-IV criteria, where… | Nov 2005 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.